Quick Takeaways
- Paradigm Biocapital Advisors LP filed SCHEDULE 13G/A for Agios Pharmaceuticals, Inc. Common Stock, $0.001 par value per share (AGIO).
- Disclosed ownership: 4.9%.
- Date of event: 30 Sep 2025.
Quoteable Key Fact
"Paradigm Biocapital Advisors LP disclosed 4.9% ownership in Agios Pharmaceuticals, Inc. Common Stock, $0.001 par value per share (AGIO) on 30 Sep 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Paradigm BioCapital Advisors LP | 4.9% | 2,873,555 | 2,873,555 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory | |
| Paradigm BioCapital Advisors GP LLC | 4.9% | 2,873,555 | 2,873,555 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory | |
| Senai Asefaw, M.D. | 4.9% | 2,873,555 | 2,873,555 | 0 | /s/ Senai Asefaw, M.D. | N/A | |
| Paradigm BioCapital International Fund Ltd. | 4.4% | 2,536,170 | 2,536,170 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory |